Lexaria Bioscience (LEXX) Retained Earnings (2011 - 2026)
Lexaria Bioscience's (LEXX) quarterly Retained Earnings came in at -$55444.0 in Q1 2026, up 99.9% year-on-year from -$27735.5 in Q1 2025, and up 99.91% quarter-over-quarter from -$65.1 million in Q4 2025.
Lexaria Bioscience (LEXX) Retained Earnings (2011 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed Retained Earnings across 16 years of filings, most recently posting -$55444.0 for Q1 2026.
- Retained Earnings for Q1 2026 came in at -$55444.0, up 99.9% year-over-year; the trailing twelve-month figure through Feb 2026 was -$55444.0 (up 99.9% YoY), and the FY2025 annual result was -$70335.0, up 99.86% from the prior year.
- Retained Earnings came in at -$55444.0 for Q1 2026 at Lexaria Bioscience, up from -$65.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$20626.0 in Q1 2024 to a low of -$65.1 million in Q4 2025.
- The 5-year median for Retained Earnings is -$40.0 million (2022), against an average of -$31.9 million.
- Across the five-year window, Retained Earnings surged 99.95% in 2024 and tumbled 282861.25% in 2025, its largest moves.
- Lexaria Bioscience's Retained Earnings stood at -$40.9 million in 2022, then retreated by 14.9% to -$46.9 million in 2023, then jumped by 99.95% to -$22991.0 in 2024, then sank by 282861.25% to -$65.1 million in 2025, then soared by 99.91% to -$55444.0 in 2026.
- The last three Retained Earnings figures came in at -$55444.0 (Q1 2026), -$65.1 million (Q4 2025), and -$70335.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -838.07 Mn |
| 10 | Lexaria Bioscience | 7.63 Mn | 2.11 Mn | 20,000.00 | -55,444.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -55,444.00 |
| Nov 30, 2025 | -65.06 Mn |
| Aug 31, 2025 | -70,335.00 |
| May 31, 2025 | -81,073.00 |
| Feb 28, 2025 | -56.98 Mn |
| Nov 30, 2024 | -22,991.00 |
| Aug 31, 2024 | -51.56 Mn |
| May 31, 2024 | -49.37 Mn |
| Feb 29, 2024 | -20,626.00 |
| Nov 30, 2023 | -46.94 Mn |
| May 31, 2023 | -44.52 Mn |
| Feb 28, 2023 | -42.15 Mn |
| Nov 30, 2022 | -40.85 Mn |
| Aug 31, 2022 | -39.10 Mn |
| May 31, 2022 | -37.63 Mn |
| Feb 28, 2022 | -35.25 Mn |
| Nov 30, 2021 | -33.82 Mn |
| Aug 31, 2021 | -31.83 Mn |
| Feb 28, 2021 | -28.09 Mn |
| Nov 30, 2020 | -28.50 Mn |